Health & Biotech
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Aussie companies jostle to become the world’s supplier of medicinal cannabis
Health & Biotech
Creso welcomes new US law making it easier to research benefits, effects of medicinal marijuana
Health & Biotech
Weed Week: Oregon pardons cannabis convictions and bulk people light up on Turkey Day
News
Closing Bell: Benchmark up, small caps flat; NYM latest to cash in on REE hit and this one’s a bit of a scandium
News
LAST ORDERS: All the wisdom you might have missed from the ASX and elsewhere today
News
ASX Small Caps Lunch Wrap: Righto… who wants their childhood completely ruined today?
Health & Biotech
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
Health & Biotech
Creso wraps up Health House acquisition, expands global cannabis footprint
Health & Biotech
Weed Week: More US states vote to legalise cannabis and Czech Republic to follow in Germany’s footsteps
Health & Biotech
Creso Pharma’s wholly-owned US subsidiary Sierra Sage Herbs expands into Canada
News
Pampered pooches: Which ASX stocks are riding the ‘humanisation of pets’ trend?
Health & Biotech
Creso Pharma subsidiary granted amended cannabis 2.0 licence in Canada
News
ASX Quarterlies: A strong quarter from these cannabis, gaming and fintech stocks
Health & Biotech
ASX Biotech Stocks: Surgeons can now be reimbursed for using Orthocell’s nerve repair device
Health & Biotech
Creso welcomes news that US cannabis banking and expungements bill is close
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
News